(Q40622456)

22 September 2017

Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia (English)

1 reference

22 September 2017

Cortes J

1

1 reference

22 September 2017

Estey E

2

1 reference

22 September 2017

Beran M

3

1 reference

22 September 2017

O'Brien S

4

1 reference

22 September 2017

Giles F

5

1 reference

22 September 2017

Koller C

6

1 reference

22 September 2017

Keating M

7

1 reference

22 September 2017

Kantarjian H

8

1 reference

22 September 2017

1 February 2000

1 reference

22 September 2017

1 reference

22 September 2017

36

1 reference

22 September 2017

479-484

1 reference

22 September 2017

5-6

1 reference

DNA topoisomerase poisons as antitumor drugs

22 September 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428190009148395

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009148395

Effects of CPT-11 in combination with other anti-cancer agents in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009148395

The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009148395

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009148395

Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009148395

10.3109/10428190009148395

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference